Related Experiment Video
Updated: Sep 27, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Preclinical and Clinical Aspects of using Tazemetostate in Human Cancers
Leila Mousazadeh1, Behzad Mousazadeh2, Jamshid Motaei3
1Department of Nursing, Kurdistan Technical Institute, Sulaymaniyah, Iraq.
Abstract:
Epigenetic drugs are novel drug categories with promising effects in different cancers. Tazemetostate is among the drugs that were recently used in clinical settings, especially in the treatment of specific tumors and lymphomas. There are a growing number of ongoing clinical trials evaluating the safety and efficacy of tazemetostate in different cancers. The present review addressed the available preclinical studies evaluating the combination of tazemetostate and other chemotherapy agents in treating different cancers and summarized the limited clinical evidence available regarding the efficacy of this novel Enhancer of Zeste Homolog 2 (EZH2) inhibitor in cancer. Based on the available clinical studies, tazemetostate could be considered a safe epigenetic agent with limited adverse events for treating specific types of lymphomas and solid tumors. However, the superiority of using tazemetostate over other chemotherapy agents in patients with cancer as well as using the drug for other clinical conditions, including non-alcoholic steatohepatitis, needs further investigation. Moreover, the effect of tazemetostate on human germline cells is clearly evaluated as some animal studies demonstrated that the drug can affect germline epigenome suggesting further studies on this issue.
Insights
Tazemetostate, an Enhancer of Zeste Homolog 2 (EZH2) inhibitor, shows promise as a safe epigenetic drug for certain lymphomas and solid tumors. Further research is needed to confirm its superiority and explore other conditions.
Area of Science:
- Oncology
- Pharmacology
- Epigenetics
Background:
- Epigenetic drugs offer novel cancer treatment strategies.
- Tazemetostate is an emerging Enhancer of Zeste Homolog 2 (EZH2) inhibitor used clinically for specific cancers.
- Ongoing trials investigate tazemetostate's safety and efficacy across various malignancies.
Purpose of the Study:
- To review preclinical data on tazemetostate combined with chemotherapy.
- To summarize current clinical evidence on tazemetostate's efficacy in cancer treatment.
- To assess the safety profile and potential applications of tazemetostate.
Main Methods:
- Review of preclinical studies on tazemetostate and chemotherapy combinations.
- Analysis of available clinical trial data for tazemetostate in cancer patients.
- Evaluation of safety and adverse event profiles from clinical studies.
Main Results:
- Tazemetostate demonstrates a favorable safety profile with limited adverse events in clinical settings.
- Evidence suggests efficacy in treating specific lymphomas and solid tumors.
- Preclinical data supports combination therapy, but clinical superiority requires more investigation.
Conclusions:
- Tazemetostate is a potentially safe epigenetic agent for specific lymphomas and solid tumors.
- Further studies are essential to establish tazemetostate's superiority over existing chemotherapy and explore new indications like non-alcoholic steatohepatitis.
- The impact of tazemetostate on the human germline epigenome warrants additional investigation based on animal study findings.
More Related Videos
Related Concept Videos
01:28Preclinical Development: Overview
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...